Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $17.86

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been assigned a consensus rating of “Hold” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $17.86.

Several equities research analysts recently weighed in on the stock. Truist Financial assumed coverage on shares of Y-mAbs Therapeutics in a research report on Friday, June 28th. They issued a “buy” rating and a $21.00 price target on the stock. HC Wainwright boosted their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, May 13th.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 7,351 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $95,563.00. Following the transaction, the insider now owns 232,681 shares in the company, valued at $3,024,853. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Thomas Gad sold 7,351 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $95,563.00. Following the completion of the sale, the insider now directly owns 232,681 shares of the company’s stock, valued at $3,024,853. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the sale, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at $2,545,285.39. The disclosure for this sale can be found here. Insiders have sold 99,444 shares of company stock worth $1,203,925 over the last quarter. Insiders own 21.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. lifted its stake in Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after acquiring an additional 1,056 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Y-mAbs Therapeutics in the fourth quarter worth about $34,000. Tower Research Capital LLC TRC lifted its stake in Y-mAbs Therapeutics by 345.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,686 shares of the company’s stock worth $46,000 after acquiring an additional 5,185 shares during the period. Bailard Inc. purchased a new stake in Y-mAbs Therapeutics in the fourth quarter worth about $115,000. Finally, Caxton Associates LP purchased a new stake in Y-mAbs Therapeutics in the first quarter worth about $306,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB opened at $12.33 on Friday. The company’s fifty day moving average is $12.05 and its 200 day moving average is $13.47. Y-mAbs Therapeutics has a fifty-two week low of $4.60 and a fifty-two week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. The business had revenue of $19.93 million during the quarter, compared to the consensus estimate of $22.06 million. As a group, sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.52 earnings per share for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.